ANIMAL HEARTS HAD MIXED RESULTS
TB-500 heart claims rely on thymosin beta-4 animal tests
The fragment is often named in claims about heart repair. Here you'll read what researchers found in animals. Most heart studies gave animals complete thymosin beta-4. A better animal heart result doesn't establish heart protection for you.
Injured mouse hearts pumped better with the larger protein
Injured mouse hearts worked better after treatment with whole thymosin beta-4. Nature reported the finding in 2004 [2]. Researchers tied a blood vessel shut to cause heart injury. Heart cells stayed alive more readily, while cells involved in repair moved.
The survival change involved several proteins inside heart cells. Together, those proteins helped cells resist dying after losing blood flow. Thymosin beta-4 also holds actin, the protein used to build strands inside cells. Those strands let a cell reshape itself or move, another step during repair.
The mouse result gave researchers a reason for further heart tests. More than a decade of work followed that early finding. Researchers wanted to learn whether treatment could limit harm after heart attacks. The first test helped mice, but doesn't establish help for your heart.
Here's why TB-500 can't simply claim the mouse result. The bigger protein has a weight of about 4963 daltons; the fragment weighs 889 daltons. Daltons are tiny lab units of weight, and the weights show how much smaller the fragment is. TB-500 shares the movement-related part, but hasn't shown the same cell-survival changes in people.
A completed human heart trial comparing the fragment with another treatment is missing. The missing trial leaves your human heart benefit unproved. If you read that treatment protected an animal heart, you need to know whether the same substance was tested in people with the same kind of heart injury as yours.
TB-500 hasn't repeated animal heart gains in people
Whole thymosin beta-4 helped animal heart cells survive and made cells on the heart surface active [2][7]. TB-500 hasn't shown those same changes in people. No completed heart trial has compared the fragment with another treatment. You can't rely on the animal changes to predict your benefit.
Mouse heart surface cells helped build a blood supply
Mouse hearts with poor blood flow grew new vessels after treatment. Whole thymosin beta-4 made cells in the heart's outer layer active [7]. Those cells moved and helped form vessels near damaged muscle. Part of the response repeated what happens as a heart develops.
The outer layer contains cells that can help build tissue. In an adult heart, those cells usually do little. Treatment with thymosin beta-4 made those cells move in the mouse study. The added vessel growth doesn't establish repair of your heart.
Developing mouse hearts also needed thymosin beta-4 to build their blood supply [8]. Nearby cells received messages through the protein, helping vessels form. A 2010 review brought those findings together with other heart-repair tests [10]. You can see why researchers kept testing the larger protein.
Both findings concern mice given full thymosin beta-4, rather than the TB-500 fragment. Neither establishes the fragment's effects in a person's heart. A comparison of human treatments would be needed to answer that question. The smaller fragment hasn't established those benefits for your heart.
Pig tests showed that heart treatment could fail
The larger-animal findings weren't all helpful. Rodents had less heart damage and better pumping with thymosin beta-4 after heart attacks [9]. A 2021 pig study found more heart-cell growth and better survival of added cells [12]. The protein also helped those added cells aid repair.
The pig result used both thymosin beta-4 and added cells. Researchers put cells intended to help tissue repair into the injured heart along with treatment. The study summary doesn't give you enough detail to explain how the treatment was delivered. Because the cells and protein were used together, you can't credit the protein alone.
Another pig test found no protection from thymosin beta-4 after a period of stopped blood flow followed by restored flow, leaving the animals without less injury from treatment [5]. For mice that lacked a protein needed by muscles, fibers grew but heart function didn't improve. A heart can show cell changes without pumping better.
Giving a treatment in different ways can change the result. Different animals and types of heart injury matter too. You have helpful findings beside failures, which leaves important questions open. The fragment hasn't been proved to repair your heart.
TB-500 heart-attack protection hasn't been proved for you
Rodents had better heart results with whole thymosin beta-4 after a heart attack or a vessel tied shut [2][9]. A separate test halted and restored blood flow in pigs, without benefit from treatment. The fragment lacks a completed human heart trial comparing treatments. You don't have proof of heart protection from the fragment.
Thymosin beta-4 trial plans don't establish completed treatment
People received thymosin beta-4 through a vein in an early Phase 1 safety test [6]. Other completed human tests used eye drops. Heart trials using shots were listed, but an early heart-attack trial was canceled before anyone joined. You're without proof that the fragment helps your heart from a planned trial alone.
The larger protein can act through parts the fragment lacks
Thymosin beta-4 has more than the section found in TB-500. Whole thymosin beta-4 has years of animal tests involving cell survival and new vessels. Researchers also moved beyond mice to test larger animals. Those tests haven't shown benefits for you from the TB-500 fragment, whose weight is 889 daltons, measured in tiny lab units.
Separate animal findings concern separate steps in repair. Heart cells survived better [2], while cells on the surface moved [7]. Developing hearts formed blood supplies [8], and rodent hearts had less damage after heart attacks [9]. You can't treat those changes as human proof for a smaller substance.
A different fragment can be released from the complete protein. That other fragment may affect scarring and new blood vessels. TB-500 lacks the section that releases the other fragment. TB-500 shares one section, but the whole protein has other actions.
Researchers would need to test the fragment's own effects in people. An idea about repeating the larger protein's results isn't a result itself. You're still waiting for proof of the fragment's effects on your heart. Animal findings can justify research without settling your treatment benefit.
Missing human proof leaves your heart question unanswered
Your heart benefit hasn't been established by the animal tests. Whole thymosin beta-4 helped some animal hearts, while other tests failed. TB-500 hasn't shown those effects in human hearts. The useful findings belong to thymosin beta-4 and don't promise you protection from TB-500.
A 2026 review found reasons to study these unapproved substances further [11]. Animal healing sometimes improved, but strong human safety proof remained scarce. Much use was taking place without close drug oversight. Better results in animals don't fill the human safety gap for you.